GO:0002058 uracil binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002058 (uracil binding) is a molecular function defined as binding to uracil, the RNA base that also arises in DNA by cytosine deamination.
• Uracil binding is central to antibody diversification, where activation-induced cytidine deaminase (AID) deaminates cytosine to uracil during somatic hypermutation and class-switch recombination.
• Uracil-DNA glycosylases such as UNG and UdgX recognize uracil in DNA; UdgX forms a covalent bond to abasic DNA after uracil excision.
• Uracil-binding pockets occur in diverse proteins, including the SARS-CoV-2 nucleocapsid RNA-binding domain and type 1 ribosome-inactivating proteins.
• Small molecules and aptamers that occupy uracil-binding sites can inhibit enzymes such as acetylcholinesterase and mismatch repair factors.
• Accurate measurement of uracil binding matters clinically, for example in dihydropyrimidine dehydrogenase (DPD) phenotyping for fluoropyrimidine therapy.
Description
GO:0002058, uracil binding, is a molecular function describing the selective non-covalent or covalent interaction of a protein or nucleic acid with uracil. Uracil is a pyrimidine base found in RNA and generated in DNA when cytosine is deaminated; this lesion is mutagenic if not repaired. Because uracil is both a normal RNA component and a DNA damage mark, proteins that bind it must discriminate between legitimate and aberrant contexts. The term therefore captures a broad set of recognition events that underpin nucleic acid metabolism, immunity, and antiviral defense. Researchers study uracil binding to understand how cells detect and process uracil-containing nucleic acids. In adaptive immunity, the deamination of cytosine to uracil by AID is the initiating event of somatic hypermutation and class-switch recombination, and downstream uracil-binding factors determine mutation outcomes. In DNA repair, uracil-DNA glycosylases bind uracil and remove it, and some family members such as UdgX remain covalently attached to the resulting abasic site. Uracil recognition is also exploited by pathogens and by proteins with unrelated folds, such as the SARS-CoV-2 nucleocapsid protein and plant ribosome-inactivating proteins. From a translational perspective, uracil binding influences drug action and toxicity. Dihydropyrimidine dehydrogenase (DPD) binds uracil and thymine as part of pyrimidine catabolism, and partial protein binding of these bases can confound DPD phenotyping used to guide fluoropyrimidine dosing. Uracil-based compounds have been developed as slow-binding acetylcholinesterase inhibitors for myasthenia gravis and organophosphate protection, and mismatch-binding molecules can interfere with repair of uracil-containing DNA. These examples show that GO:0002058 is not a narrow biochemical curiosity but a recurring recognition principle with therapeutic relevance.
uracil binding At A Glance
| GO ID | GO:0002058 |
|---|---|
| GO term | uracil binding |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Major function | Selective recognition of uracil by proteins or nucleic acids |
| Example protein families | Uracil-DNA glycosylases (UNG, UdgX), AID/APOBEC enzymes, ribosome-inactivating proteins, viral nucleocapsid proteins |
| Representative ligands | Uracil, uridine, uracil-containing DNA or RNA |
| Disease relevance | Antibody deficiency, cancer mutagenesis, fluoropyrimidine toxicity, viral replication |
| Research methods | Crystallography, cryo-EM, fluorescence binding assays, CRISPR knockout models |
What Is GO:0002058?
In the Gene Ontology, GO:0002058 (uracil binding) is defined as binding to uracil. It is a molecular_function term, meaning it describes what a gene product does at the molecular level rather than a pathway or location. The function is satisfied when a protein, peptide, or nucleic acid aptamer forms a stable interaction with uracil, whether through hydrogen bonding in a base-specific pocket, stacking interactions, or, in specialized enzymes, a covalent linkage after catalysis. The term does not specify the biological outcome of binding; that context is supplied by associated processes such as DNA repair, RNA metabolism, or immune diversification.
Why Is uracil binding Important in Cell Biology?
Uracil binding is important because uracil is a dual-meaning base: it is essential in RNA but abnormal in DNA, and its recognition determines whether cells repair, mutate, or tolerate a given nucleic acid. Errors in uracil recognition contribute to antibody diversification defects, genome instability, and altered drug responses. The same binding principle is used by pathogens and by proteins with diverse folds, making it a target for antiviral and antiparasitic strategies. Consequently, GO:0002058 connects fundamental nucleic acid biochemistry to immunology, cancer biology, and clinical pharmacology.
• Uracil binding initiates antibody somatic hypermutation and class-switch recombination through AID-mediated cytosine deamination.
• Uracil-DNA glycosylases bind uracil in DNA and remove it, preventing C-to-T transition mutations.
• UdgX forms a covalent bond to abasic DNA after uracil excision, providing a unique model of uracil-dependent covalent capture.
• The SARS-CoV-2 nucleocapsid protein contains a uracil-binding pocket that can be targeted by stem-loop DNA aptamers.
• Type 1 ribosome-inactivating proteins bind uracil and uridine, informing studies of plant toxin specificity.
• Mismatch-binding molecules can inhibit repair of uracil-containing DNA, linking uracil recognition to repair pathway inhibition.
• Uracil-based inhibitors of acetylcholinesterase are explored for myasthenia gravis and organophosphate poisoning.
• DPD binding of uracil and thymine affects phenotyping that guides fluoropyrimidine chemotherapy dosing.
Molecular Mechanism of uracil binding
Base-specific recognition pocket
In simple terms: Proteins use a pocket shaped to fit uracil and form hydrogen bonds with it.
Uracil-binding proteins typically present a pocket that complements the pyrimidine ring and its exocyclic oxygens and nitrogens. Structural studies of type 1 ribosome-inactivating proteins from Momordica balsamina show complexes with uracil and uridine, revealing how aromatic residues and hydrogen-bond donors position the base. In the SARS-CoV-2 nucleocapsid RNA-binding domain, a compact stem-loop DNA aptamer targets a uracil-binding pocket, demonstrating that nucleic acids can also evolve to occupy such sites. These examples illustrate that uracil recognition is achieved through a combination of shape complementarity and specific hydrogen bonding rather than a single conserved motif.
Uracil excision and covalent capture
In simple terms: Some enzymes cut uracil out of DNA and then stay attached to the leftover site.
Uracil-DNA glycosylases of the UdgX family bind uracil in DNA and catalyze excision, but unlike canonical UNG they form a covalent bond to the resulting abasic DNA. Ahn et al. showed that UdgX covalently binds abasic DNA upon uracil excision, providing a structural and mechanistic basis for this unusual behavior. Sang et al. identified a unique uracil-DNA binding protein of the uracil DNA glycosylase superfamily, expanding the known diversity of uracil recognition within this family. This mechanism is relevant to understanding how cells handle uracil lesions and how some enzymes can be trapped on DNA.
Uracil in antibody diversification
In simple terms: In immune cells, uracil is deliberately made in DNA to create antibody diversity.
Activation-induced cytidine deaminase (AID) converts cytosine to uracil in immunoglobulin genes, initiating somatic hypermutation and class-switch recombination. Di Noia and Neuberger reviewed the molecular mechanisms of antibody somatic hypermutation, emphasizing that uracil generated by AID is recognized by base excision repair and mismatch repair factors, leading to mutations or strand breaks. Thus, uracil binding is not only a repair function but also a programmed event in adaptive immunity. The balance between error-prone and error-free processing of uracil determines antibody affinity and isotype.
Uracil binding in drug metabolism and phenotyping
In simple terms: A drug-metabolizing enzyme binds uracil, and this binding can affect clinical tests.
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in pyrimidine catabolism and binds uracil and thymine. van den Wildenberg et al. reported that partial protein binding of uracil and thymine affects accurate DPD phenotyping, which is used to predict fluoropyrimidine toxicity. This finding highlights that uracil binding is not only a structural event but also a variable that can confound clinical assays. Researchers studying DPD must therefore account for binding equilibria when interpreting enzyme activity.
Small-molecule and aptamer modulation of uracil binding
In simple terms: Drugs and aptamers can block or mimic uracil binding to change enzyme activity.
Uracil moieties have been used to design slow-binding reversible acetylcholinesterase inhibitors for possible treatment of myasthenia gravis and protection from organophosphate poisoning. Separately, mismatch-binding molecules can inhibit the repair reaction of uracil-containing DNA, showing that uracil recognition can be targeted to modulate repair. These approaches demonstrate that the uracil-binding pocket is a druggable site. They also provide chemical tools to probe the biological consequences of blocking uracil recognition.
Key Genes Involved in GO:0002058 uracil binding
The following genes and proteins represent major experimental models for studying uracil binding across DNA repair, immunity, viral replication, and drug metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AICDA (AID) | Deaminates cytosine to uracil in immunoglobulin genes | Central to somatic hypermutation and class-switch recombination |
| UNG | Uracil-DNA glycosylase that removes uracil from DNA | Model for base excision repair and uracil recognition |
| UdgX | Bacterial uracil-DNA glycosylase that covalently binds abasic DNA | Unique covalent capture mechanism after uracil excision |
| DPYD | Dihydropyrimidine dehydrogenase binds uracil and thymine | Clinically relevant for fluoropyrimidine dosing and phenotyping |
| ACHE | Acetylcholinesterase targeted by uracil-based inhibitors | Drug design for myasthenia gravis and organophosphate poisoning |
| N (SARS-CoV-2) | Nucleocapsid protein with a uracil-binding pocket | Antiviral aptamer target |
| Mismatch repair factors | Recognize uracil-containing DNA and initiate repair | Inhibited by mismatch-binding molecules |
| RIP (Momordica balsamina) | Type 1 ribosome-inactivating protein binds uracil and uridine | Structural model for uracil recognition in plant toxins |
| APOBEC family | Cytidine deaminases related to AID | Potential off-target uracil generation in cancer |
| TDG | Thymine DNA glycosylase, related to uracil processing | Context for base excision repair of deaminated bases |
| MBD4 | Methyl-CpG-binding domain protein 4 | Uracil recognition at CpG sites in repair |
| SMUG1 | Single-strand selective monofunctional uracil DNA glycosylase | Alternative uracil excision pathway |
| POLB | DNA polymerase beta in base excision repair | Downstream of uracil removal |
| XRCC1 | Scaffold in base excision repair | Coordinates uracil repair complexes |
| LIG3 | DNA ligase III in base excision repair | Completes repair after uracil excision |
| PCNA | Proliferating cell nuclear antigen | Coordinates repair and replication at uracil sites |
| RPA | Single-stranded DNA-binding protein | Protects intermediates during uracil repair |
How Is uracil binding Regulated?
Uracil binding is regulated at multiple levels. The expression of AID is tightly controlled because off-target deamination can cause mutations in non-immunoglobulin genes. Uracil-DNA glycosylases are regulated by cell cycle, localization, and post-translational modifications, which determine whether uracil is repaired or tolerated. In clinical settings, DPD activity and uracil binding are influenced by genetic polymorphisms and by the presence of substrate, affecting phenotyping accuracy. Small molecules and aptamers can also modulate uracil binding directly, as shown for acetylcholinesterase inhibitors and mismatch-binding molecules. Together, these layers ensure that uracil recognition is context-dependent and responsive to cellular state.
uracil binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AICDA | Hyper-IgM syndrome, antibody deficiency | AICDA knockout B cell lines and mouse models |
| UNG | Cancer predisposition, mutagenesis | UNG knockout cell lines and repair assays |
| DPYD | Fluoropyrimidine toxicity | DPYD knockdown or point-mutation models for phenotyping |
| N (SARS-CoV-2) | Viral replication | Nucleocapsid overexpression and aptamer binding assays |
| ACHE | Myasthenia gravis, organophosphate poisoning | Enzyme inhibition assays with uracil-based compounds |
Antibody deficiency and immune dysregulation
AID-mediated uracil generation is essential for antibody diversification, and defects in this pathway cause hyper-IgM syndrome and impaired humoral immunity. Because uracil binding by downstream repair factors determines mutation outcomes, perturbations can lead to autoimmunity or immunodeficiency. Studying uracil recognition in B cells therefore informs both basic immunology and clinical management of antibody deficiencies.
Cancer mutagenesis and therapy response
Uracil in DNA is mutagenic if unrepaired, and APOBEC-mediated deamination contributes to mutational signatures in cancer. Uracil-DNA glycosylase activity and mismatch repair status influence whether uracil lesions are repaired or become mutations. In addition, DPD binding of uracil affects fluoropyrimidine metabolism, and altered DPD activity is associated with severe toxicity. These connections make uracil binding relevant to cancer risk and chemotherapy safety.
Viral replication and antiviral targeting
The SARS-CoV-2 nucleocapsid protein contains a uracil-binding pocket that can be engaged by a stem-loop DNA aptamer, suggesting a route to antiviral intervention. Because nucleocapsid is critical for viral RNA packaging, disrupting its uracil recognition could impair replication. This example illustrates how uracil-binding sites in viral proteins can be exploited therapeutically.
Neurological and toxicological applications
Uracil-based slow-binding inhibitors of acetylcholinesterase are being explored for myasthenia gravis and protection from organophosphate poisoning. These compounds act at the enzyme active site and demonstrate that uracil recognition can be harnessed for neuropharmacology. The same principle may apply to other enzymes that bind uracil or uridine.
From uracil binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of uracil binding impair antibody diversification? | AICDA or UNG knockout B cell lines |
| Does covalent uracil capture affect DNA repair? | UdgX point-mutation or knockout bacterial models |
| How does DPD uracil binding affect drug metabolism? | DPYD knockdown or knock-in cell lines |
| Can uracil-binding pockets be targeted by aptamers? | SARS-CoV-2 N overexpression with aptamer binding assays |
| Do mismatch-binding molecules inhibit uracil repair? | Mismatch repair-proficient and deficient cell lines |
| What is the structural basis of uracil recognition? | Recombinant protein expression and crystallography |
How to Study the uracil binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of uracil-protein complexes | Defining uracil-binding pockets |
| Cryo-EM | Structures of large complexes with uracil | Studying repair and viral proteins |
| Isothermal titration calorimetry | Binding affinity and thermodynamics | Quantifying uracil binding |
| Fluorescence polarization | Binding of fluorescent uracil probes | Screening inhibitors or aptamers |
| Next-generation sequencing | Mutation spectra after uracil generation | Analyzing AID off-target effects |
| Enzyme activity assays | Catalytic turnover in presence of uracil | DPD and acetylcholinesterase studies |
| Aptamer selection | Enrichment of uracil-binding nucleic acids | Targeting viral nucleocapsid |
| Mismatch repair assays | Repair of uracil-containing DNA | Testing mismatch-binding molecules |
Structural biology of uracil recognition
X-ray crystallography and cryo-electron microscopy can resolve uracil-bound complexes, as shown for type 1 ribosome-inactivating proteins with uracil and uridine and for UdgX covalently bound to abasic DNA. These methods reveal the atomic details of hydrogen bonding and stacking that define specificity. They are essential for rational design of inhibitors or aptamers that target uracil-binding pockets.
Biochemical binding assays
Fluorescence polarization, isothermal titration calorimetry, and filter-binding assays can quantify affinity for uracil or uracil-containing nucleic acids. Such assays are used to characterize DPD binding of uracil and thymine and to evaluate mismatch-binding molecules that interfere with repair. They provide quantitative parameters for comparing wild-type and mutant proteins.
Cell-based repair and mutation assays
Reporter assays and next-generation sequencing can measure uracil-induced mutations and repair efficiency. In B cells, AID-dependent somatic hypermutation can be tracked by sequencing immunoglobulin genes. In DNA repair studies, uracil-containing substrates can be introduced into cells to monitor excision and repair. These approaches link molecular binding to biological outcomes.
Pharmacological and phenotypic profiling
Enzyme activity assays and phenotyping tests are used to study DPD and acetylcholinesterase in the context of uracil binding. These methods can reveal how binding equilibria affect clinical readouts. They are also used to evaluate the potency of uracil-based inhibitors.
How CRISPR Can Be Used to Study GO:0002058 uracil binding
Knockout
CRISPR knockout of genes such as AICDA, UNG, or DPYD can abolish uracil binding and reveal its contribution to antibody diversification, DNA repair, or drug metabolism. Knockout cell lines provide clean backgrounds for rescue experiments with wild-type or binding-deficient alleles. They are also useful for identifying synthetic lethal interactions with uracil-processing pathways.
Point Mutation
Point mutations in uracil-binding pockets can dissociate binding from catalysis. For example, mutating residues that contact uracil in UdgX or ribosome-inactivating proteins can test whether covalent capture or substrate recognition is required for function. Such mutants are valuable for structure-function studies and for validating drug targets.
Knock-in
Knock-in of tagged or fluorescently labeled uracil-binding proteins allows real-time tracking of localization and dynamics. Tagged AID or UNG can be used to monitor recruitment to DNA lesions or immunoglobulin loci. Knock-in of disease-associated variants can model altered uracil binding in a physiological context.
Overexpression
Overexpression of uracil-binding proteins such as SARS-CoV-2 N or DPD can amplify binding signals for biochemical and structural studies. It can also reveal dominant-negative or gain-of-function phenotypes. Overexpression models are particularly useful when endogenous protein levels are low.
How EDITGENE Supports uracil binding Research
Researchers studying uracil binding-related genes often need to determine whether a candidate gene is causally involved in a specific repair, immune, or metabolic phenotype. EDITGENE provides CRISPR-based cell models that enable precise perturbation of uracil-binding proteins, from complete knockout to single-amino-acid changes, so that binding and function can be dissected with confidence.
Contact EDITGENE today to design your custom CRISPR model for uracil binding research.
Frequently Asked Questions About uracil binding
What is uracil binding?
Uracil binding (GO:0002058) is a molecular function defined as binding to uracil, the pyrimidine base found in RNA and generated in DNA by cytosine deamination.
What genes are involved in uracil binding?
Key genes include AICDA (AID), UNG, UdgX, DPYD, and viral genes such as SARS-CoV-2 N, as well as ribosome-inactivating protein genes.
What is the GO ID for uracil binding?
The Gene Ontology ID for uracil binding is GO:0002058, under the molecular_function aspect.
How is uracil binding studied?
It is studied by crystallography, cryo-EM, binding assays, enzyme activity assays, and CRISPR knockout or point-mutation models.
Why is uracil binding important in immunology?
AID deaminates cytosine to uracil in immunoglobulin genes, and uracil recognition by repair factors drives somatic hypermutation and class-switch recombination.
What diseases are linked to uracil binding?
Antibody deficiency, cancer mutagenesis, fluoropyrimidine toxicity, and viral replication are linked to uracil-binding proteins.
Can uracil binding be targeted by drugs?
Yes, uracil-based acetylcholinesterase inhibitors and mismatch-binding molecules show that uracil-binding sites can be modulated pharmacologically.
What is the role of UdgX in uracil binding?
UdgX is a uracil-DNA glycosylase that covalently binds abasic DNA after uracil excision, providing a unique mechanism of uracil capture.
How does DPD bind uracil?
Dihydropyrimidine dehydrogenase binds uracil and thymine, and partial protein binding can affect DPD phenotyping used for fluoropyrimidine dosing.
What model systems are used for uracil binding research?
Common models include knockout and point-mutation cell lines, overexpression systems, and structural biology preparations.
Conclusion
GO:0002058 (uracil binding) captures a fundamental recognition event that spans DNA repair, antibody diversification, viral replication, and drug metabolism. The diversity of proteins that bind uracil, from AID and UNG to UdgX, DPD, and viral nucleocapsid, underscores its broad biological importance. Understanding the structural and mechanistic basis of uracil binding provides opportunities for therapeutic intervention and for interpreting clinical phenotypes. Continued research using CRISPR models and structural methods will clarify how uracil recognition is regulated and how it can be targeted.
References
- 1. Di Noia JM et al.. 2007. Molecular mechanisms of antibody somatic hypermutation.. Annu Rev Biochem 76:1-22 PMID: 17328676
- 2. Ahn WC et al.. 2019. Covalent binding of uracil DNA glycosylase UdgX to abasic DNA upon uracil excision.. Nat Chem Biol 15(6):607-614 PMID: 31101917
- 3. van den Wildenberg SAH et al.. 2024. Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping.. J Pharm Biomed Anal 249:116381 PMID: 39067280
- 4. Saifina LF et al.. 2023. Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.. Eur J Med Chem 246:114949 PMID: 36462442
- 5. Esler MA et al.. 2024. A compact stem-loop DNA aptamer targets a uracil-binding pocket in the SARS-CoV-2 nucleocapsid RNA-binding domain.. Nucleic Acids Res 52(21):13138-13151 PMID: 39380503
- 6. Ulhusna A et al.. 2022. Inhibitory Effects of Mismatch Binding Molecules on the Repair Reaction of Uracil-Containing DNA.. Biochemistry 61(22):2522-2530 PMID: 36250600
- 7. Sang PB et al.. 2015. A unique uracil-DNA binding protein of the uracil DNA glycosylase superfamily.. Nucleic Acids Res 43(17):8452-63 PMID: 26304551
- 8. Pandey SN et al.. 2019. Binding and structural studies of the complexes of type 1 ribosome inactivating protein from Momordica balsamina with uracil and uridine.. Proteins 87(2):99-109 PMID: 30007053
